Cresset Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Cresset Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,728	Closed	-$258K	–	1046
2021 Q1	$258K	Buy	+5,728	New	+$319K	﹤0.01%	746
2019 Q2	–	Sell	-865	Closed	-$70K	–	1042
2019 Q1	$70K	Buy	865 +110	+15%	+$7.1K	﹤0.01%	671
2018 Q4	$41K	Buy	+755	New	+$38.5K	﹤0.01%	539

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Cresset Asset Management's IONS Position: Q2 2021 in Review

Cresset Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2021, closing a stake of 5,728 shares — an estimated $258K sold.

Cresset Asset Management first reported a position in IONS in Q4 2018 and held it in 3 quarters. The position peaked at $258K in Q1 2021. 337 funds tracked by Wall St. Rank hold IONS as of Q2 2021.

Cresset Asset Management reported no remaining Ionis Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Cresset Asset Management sold 5,728 Ionis Pharmaceuticals shares in Q2 2021, an estimated $258K.
Cresset Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Cresset Asset Management's Ionis Pharmaceuticals position peaked at $258K in Q1 2021.
337 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2021.

Based on Cresset Asset Management's 13F filing for Q2 2021, filed 10 Aug 2021.